Clonally expanded effector CD4 + cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy
Authors:
- Ambre Manon GiguelayAGAmbre Manon Giguelay
- Patrick MaschmeyerPMPatrick Maschmeyer
- Leonie Müller-JensenLMLeonie Müller-Jensen
- Manpreet MeyerMMManpreet Meyer
- Petra HuehnchenPHPetra Huehnchen
- Wolfgang BoehmerleWBWolfgang Boehmerle
- Matthias EndresMEMatthias Endres
- Samuel KnaussSKSamuel Knauss
- Leif S. LudwigLLLeif S. Ludwig
Open Access
- 30 October 2025
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (10) , e012350
Abstract
Background: Immune checkpoint inhibitor (ICI) therapies present a pillar of modern cancer therapy but can cause neurological immune-related adverse events (n-irAEs), of which up to 35% are severe or even fatal. However, the detailed immunological mechanisms and risk factors underlying n-irAEs remain largely unknown. Here, we leveraged single-cell genomics to dissect immune cell type, state, and clonal heterogeneity associated with n-irAEs. Methods: We performed coupled single-cell RNA sequencing and T cell receptor (TCR) profiling on peripheral blood cells of 17 patients with cancer receiving ICI therapy, including 8 patients with acute neurotoxicity. This approach enabled integrated analyses of immune cell states and T cell clonality linked to ICI-induced n-irAEs. Results: We profiled 186 435 immune cells and conducted pseudotime analyses, revealing that patients with n-irAEs, compared with controls, present with clonally expanded CD4 + cytotoxic T lymphocytes (CD4 + CTLs) with an n-irAE-specific effector gene expression profile. These T cells predominantly belong to a select set of expanded clonal families and express genes linked to antigen-induced activation, cell lysis, and neuroinflammation. Moreover, they highly express CXCR3 (FC=2.03 compared with control CD4 + CTLs, with a false discovery rate=7.7×10⁻⁴), encoding the chemokine receptor of CXCL10, previously nominated as a biomarker for severe ICI therapy-induced n-irAEs with concomitant multiple organ system toxicity. Conclusions: Overall, our study highlights the expansion and activation of CD4 + CTLs in ICI-induced neurotoxicity, proposing these cells as potential targets for developing new biomarkers and therapeutic strategies to improve patient outcomes.Keywords
Funding Information
- Berlin Institute of Health (Charité Clinician Scientist Program)
- Paul-Ehrlich-Gesellschaft Stiftung (N/A)
- Hector Fellow Academy (N/A)
- European Molecular Biology Organization (Young Investigator Programme)
- Deutsche Forschungsgemeinschaft (Clinical Research Group KFO 5023 BeCAUSE-Y, EXC-2049 – 390688087, Emmy Noether fellowship / LU 2336/2-1, Heinz Maier-Leibnitz Award, LU 2336/3-1, LU 2336/6-1, SFB1588, STA 1586/5-1, TRR 295-424778381, TRR241, project 2 EN343/16-1)
- Else Kröner-Fresenius-Stiftung (2020_EKEA.80)
- National Human Genome Research Institute (UM1 HG012076)
This publication has 49 references indexed in Scilit:
- Isoforsythiaside confers neuroprotection against Alzheimer’s disease by attenuating ferroptosis and neuroinflammation in vivo and in vitroFood Science and Human Wellness, 2023
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Integrated analysis of multimodal single-cell dataCell, 2021
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung CancerJAMA Oncology, 2019
- DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest NeighborsCell Systems, 2019
- CD69: from activation marker to metabolic gatekeeperEuropean Journal of Immunology, 2017
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and mTORC1 Kinase ActivationImmunity, 2014
- The Many Roles of FAS Receptor Signaling in the Immune SystemImmunity, 2009